Monte Rosa Therapeutic (GLUE) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Molecular glue platform
True small-molecule degraders bind ubiquitin ligases and reshape their surface to create a new protein-protein interaction, enabling selective protein removal; selectivity is intended to support safety.
The approach is being applied across multiple disease areas.
MRT-8102 and indication strategy
MRT-8102 targets the NLRP3 inflammasome in sterile inflammation linked to intrinsic metabolites; prioritized indications are gout, ASCVD and hidradenitis suppurativa (HS).
Gout was viewed as potentially the lowest-risk indication, supported by clinical and preclinical validation; ASCVD remains a focus despite the ZEUS trial outcome, while HS carries risk from placebo overperformance in the field.
Management attributed ZEUS limitations to IL-6 inhibition leaving ~20%-25% of IL-6 active and trial-design issues, including comorbidities; the ASCVD program will target the pathway further upstream and use a different design.
Gout phase II
GEMINI-1 is a small, two-dose study with an open-label expansion; frequent-flare patients start therapy during an acute flare, with prevention of subsequent flares as the key outcome.
The trial was on track to initiate in Q4 2026, with a data readout guided for H2 2027; management expressed confidence in timely recruitment.
Historical untreated flare rates are 50%-60% over 3-6 months; cutting that rate in half was described as a meaningful benchmark, subject to the recruited population and its characteristics.
The study will not use placebo control; historical data and prior IL-1β antibody results were cited as context for interpreting flare reduction.
Latest events from Monte Rosa Therapeutic
- GFORCE-2, VAV1 trials and early prostate cancer responses advance a multi-program pipeline.GLUE
UBS Global Biopharma Conference 2026 - NEK7, VAV1 and oncology programs advance across clinical studies.GLUE
3rd Annual Guggenheim Healthcare Innovation Conference - A $50M Novartis milestone drove Q3 profit as clinical programs advanced and runway extends into 2029.GLUE
Q3 2026 - MRT-8102 showed potent NEK7 degradation, biomarker normalization, and strong safety in Phase I.GLUE
Study result - Advancing targeted protein degraders in inflammation, autoimmune, and oncology with strong financial runway.GLUE
Wells Fargo 21st Annual Healthcare Conference - Advancing three first-in-class MGD programs with strong pharma partnerships and robust clinical data.GLUE
Corporate presentation - Q2 2026 net loss rose on lower collaboration revenue and higher R&D; cash runway extends to 2029.GLUE
Q2 2026 - Pipeline advances in oncology and autoimmunity set up major clinical milestones for the coming year.GLUE
Jefferies Global Healthcare Conference 2025 - Strong pipeline progress, Novartis deal, and $377M cash position support growth into 2028.GLUE
Q4 2024